Sales & Marketing News | pharmaphorum

News

Chiesi has named Flagship's David Khougazian as its new permanent chief executive, following the departure of Giuseppe Accogli earlier this year.

News

The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.

News

Scholar Rock has won its first product approval, on its second attempt, as the FDA gives a green light to its spinal muscular atrophy drug Isembyld.

News

The offer for Recordati by private equity firms CVC and GBL undervalues the company and is unfair to minority shareholders, claims activist investor.

News

Embroiled in a fight to retain market share in weight loss and diabetes therapies, Novo Nordisk has rebranded and launched a new corporate culture.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.